SEARCH

SEARCH BY CITATION

References

  • 1
    Centers for Disease Control and Prevention. Hepatitis A information for health professionals. http://www.cdc.gov/hepatitis/HAV/StatisticsHAV.htm, Accessed on 30 November, 2012.
  • 2
    Broman M, Jokinen S, Kuusi M, Lappalainen M, Roivainen M, Liitsola K, et al. Epidemiology of hepatitis A in Finland in 1990–2007. J Med Virol 2010; 82: 934-941.
  • 3
    Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998; 128: 111-114.
  • 4
    Brown GR, Persley K. Hepatitis A epidemic in the elderly. South Med J 2002; 95: 826-833.
  • 5
    Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver disease?. Am J Gastroenterol 1995; 90: 201-205.
  • 6
    Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290.
  • 7
    Ida S, Tachikawa N, Nakajima A, Daikoku M, Yano M, Kikuchi Y, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002; 34: 379-385.
  • 8
    Advisory Committee on Immunization Practice. Recommended adult immunization schedule: United States, 2012. Ann Intern Med 2012; 156: 211-217.
  • 9
    Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997; 176: 1064-1067.
  • 10
    Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187: 1327-1331.
  • 11
    Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, Kessler H, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000; 14: 11-21.
  • 12
    Hess G, Clemens R, Bienzle U, Schönfeld C, Schunck B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46: 40-42.
  • 13
    Tilzey AJ, Palmer SJ, Harrington C, O'Doherty MJ. Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996; 14: 1039-1041.
  • 14
    Weinberg A, Gona P, Nachman SA, Defechereux P, Yogev R, Hughes W, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193: 302-311.
  • 15
    Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC Study. J Acquir Immune Defic Syndr 2008; 49: 272-275.
  • 16
    Sun HY, Kung HC, Ho YC, Chien YF, Chen MY, Sheng WH, et al. Seroprevalence of hepatitis A virus infection in persons with HIV infection in Taiwan: implications for hepatitis A vaccination. Int J Infect Dis 2009; 13: e199-e205.
  • 17
    Tseng YT, Sun HY, Chang SY, Wu CH, Liu WC, Wu PY, et al. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18–40 years in Taiwan. J Formos Med Assoc 2012; 101: 431-438.
  • 18
    Santagostino E, Gringeri A, Rocino A, Zanetti A, de Biasi R, Mannucci PM. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994; 72: 508-510.
  • 19
    Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007; 14: 189-193.
  • 20
    Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, et al. Long-term durability of immune response after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011; 203: 1815-1823.
  • 21
    Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305: 1432-1440.
  • 22
    Kernéis S, Desaint C, Brichler S, Rey D, Belarbi L, Gordien E, et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr 2011; 57: e63-e66.